Alzheimer’s drug granted accelerated approval by FDA. These are the risks
CNN’s Sanjay Gupta reports the US Food and Drug Administration granted accelerated approval for the Alzheimer’s disease drug Lecanemab, one of the first experimental dementia drugs to appear to slow the progression of cognitive decline.
More News
Hear what Columbia and student protesters are negotiating | CNN
Jude Bellingham wins Laureus’ Breakthrough of the Year award | CNN
‘Greed is driving the train’: Why women are considered a bad bet in Nashville | CNN